ASCO: Favorable Data For J&J Combo in 1L NSCLC Gain Attention

 
• By Jung Won Shin

Positive new and updated data at ASCO for Rybrevant plus lazertinib could position the combo more strongly against Tagrisso in the first-line treatment of high-risk, EGFR-mutated non-small lung cancer. 

attention
New Standard Of Care For EGFR-mutated NSCLC On Horizon? • Source: Shutterstock

More from ASCO

More from Conferences